Biotech Business - August 30, 2021
AlzeCure receives approval from the Medical Products Agency
The company has received approval to be able to give additional doses of ACD856 in their clinical phase I study (single ascending dose, SAD) with ACD856, as its good tolerability enables higher doses to be tested. Data from the SAD study establish that ACD856, the lead candidate drug within the company’s NeuroRestore platform, shows good […]
Biotech Business - August 18, 2021
Cereno Scientific collaborates with Abbott
Cereno Scientific has announced that a collaboration agreement has been entered with Abbott regarding use of its CardioMEMS HF System in the upcoming Phase II study with Cereno’s drug candidate CS1. The technology will be used to remotely and continously monitor the pulmonary pressure in the Phase II study evaluating CS1 for the treatment of […]
Biotech Business - August 11, 2021
Almi Invest invests in Strike Pharma
Almi Invest will invest just over 2 million SEK in the newly founded Uppsala-based company Strike Pharma. As previously reported by NLS, an immunotherapeutic cancer vaccine delivery-platform has been developed at the SciLifeLab Drug Discovery and Development platform (DDD). The researchers will continue to develop the method within the framework of the newly started company, […]
Biotech Business - August 10, 2021
Toleranzia proposes directed share issue of 42 million SEK
The purpose of the share issue is to fund an enhanced clinical trial program that can shorten the development time and increase the commercial potential of the company’s drug candidate TOL2 – one of the company’s potentially curative treatments for severe autoimmune diseases. TOL2, is being developed to cure myasthenia gravis – an autoimmune nerve […]
Agreement - August 6, 2021
Nanoform and Boehringer Ingelheim execute master services agreement
The two companies have executed a master services agreement (MSA) to initiate projects in the pre-clinical early development space. The aim with the agreement is to solve the challenge of poor bioavailability and solubility in new drug candidates. “Wider uptake of the latest technological innovations is essential to address the low success rates for new […]
Biotech Business - August 3, 2021
AstraZeneca’s Saphnelo approved in the US
Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This marks the first regulatory approval for a type I interferon (type I IFN) receptor antagonist and the only new treatment approved for SLE in more than 10 […]
